Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Multiple Myeloma 57Recurrence 7Neoplasms, Plasma Cell 5Neoplasms 4Smoldering Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Immunoglobulin Light-chain Amyloidosis 1Glioblastoma 1Disease 1Chromosome 17 deletion 1

Interventions

venetoclax 26ibrutinib 23Rituximab 22Cyclophosphamide 21obinutuzumab 18acalabrutinib 18fludarabine phosphate 13fludarabine 13zanubrutinib 8Bendamustine Hydrochloride 8pirtobrutinib 7Biopsy 7Specimen Handling 6Lenalidomide 6CT-P10 6Whole-Body Irradiation 5Tacrolimus 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4duvelisib 3Melphalan 3Chlorambucil 3Busulfan 3idelalisib 2daratumumab 2Vincristine 2Prednisone 2Patient Reported Outcome Measures 2Observation 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × daratumumab × Clear all
NCT03447808 2026-01-07

Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia

Ohio State University Comprehensive Cancer Center

Phase 1 Active not recruiting
15 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03734198 2025-11-26

IDA53

French Innovative Leukemia Organisation

Phase 2 Active not recruiting
29 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡